Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 219
- Registration Number
- NCT00372996
- Locations
- 🇦🇷
Instituto de Investigaciones Clinicas, Rosario, Santa Fe, Argentina
🇧🇪UZ Gasthuisberg, Medische Oncologie, Leuven, Belgium
🇦🇷Centro Oncologico Rosario, Rosario, Santa Fe, Argentina
Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2010-12-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 13
- Registration Number
- NCT00357110
- Locations
- 🇳🇴
Research SIte, Porsgrunn, Norway
🇳🇴Research Site, Trondheim, Norway
Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
- Conditions
- Endometrial Carcinoma
- First Posted Date
- 2006-06-07
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT00334295
- Locations
- 🇩🇪
Research Site, Rostock, Germany
Faslodex Advanced Breast Cancer Local Chinese Study
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 234
- Registration Number
- NCT00327769
- Locations
- 🇨🇳
Research Site, Xi AN, China
Faslodex 500mg Multiple Dose Tolerability Study in BC Patients
- Conditions
- Advanced Breast Cancer
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2010-11-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00328120
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg
- Conditions
- Advanced Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2020-01-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 144
- Registration Number
- NCT00313170
- Locations
- 🇹🇷
Research Site, Istanbul, Turkey
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg
- Conditions
- Advanced Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 143
- Registration Number
- NCT00305448
- Locations
- 🇯🇵
Research Site, Shizuoka, Japan
Faslodex in McCune-Albright Syndrome
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00278915
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 205
- Registration Number
- NCT00274469
- Locations
- 🇬🇧
Research Site, Edinburgh, United Kingdom
SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer
- Conditions
- Breast Neoplasms
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2007-02-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 93
- Registration Number
- NCT00272740
- Locations
- 🇨🇭
Research Site, St.Gallen, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.